High plasma calcium and influencing factors in interstitial plasma cell pneumonia in infants.

N. Hallman,H. Tahka,E. Ahvenainen

Abstract:

What problem does this paper attempt to address?

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B Johnson,Ryan J Sullivan,Patrick A Ott,Matteo S Carlino,Nikhil I Khushalani,Fei Ye,Alexander Guminski,Igor Puzanov,Donald P Lawrence,Elizabeth I Buchbinder,Tejaswi Mudigonda,Kristen Spencer,Carolin Bender,Jenny Lee,Howard L Kaufman,Alexander M Menzies,Jessica C Hassel,Janice M Mehnert,Jeffrey A Sosman,Georgina V Long,Joseph I Clark

DOI: https://doi.org/10.1001/jamaoncol.2015.4368

Abstract:Importance: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. Objective: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. Design, setting, and participants: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. Exposure: Ipilimumab therapy. Main outcomes and measures: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. Results: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. Conclusions and relevance: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

A.M. Menzies,D.B. Johnson,S. Ramanujam,V.G. Atkinson,A.N.M. Wong,J.J. Park,J.L. McQuade,A.N. Shoushtari,K.K. Tsai,Z. Eroglu,O. Klein,J.C. Hassel,J.A. Sosman,A. Guminski,R.J. Sullivan,A. Ribas,M.S. Carlino,M.A. Davies,S.K. Sandhu,G.V. Long

DOI: https://doi.org/10.1093/annonc/mdw443

IF: 51.769

2017-02-01

Annals of Oncology

Abstract:Background: Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immune-related adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients.Patients and methods: Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified.Results: One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren's syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3-4) and 8 (12%) discontinued treatment. There were no treatment-related deaths.Conclusions: In melanoma patients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.

oncology
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren J Brown,Alison Weppler,Prachi Bhave,Clara Allayous,J Randall Patrinely Jr,Patrick Ott,Shahneen Sandhu,Andrew Haydon,Celeste Lebbe,Douglas B Johnson,Georgina V Long,Alexander A Menzies,Matteo S Carlino

DOI: https://doi.org/10.1136/jitc-2020-002121

Abstract:Background: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has been examined in retrospective studies, no data are available for combination therapy which has significantly higher toxicity risk. We sought to establish the safety and efficacy of combination immunotherapy for patients with advanced melanoma and pre-existing autoimmune diseases. Methods: We performed a retrospective study of patients with advanced melanoma and pre-existing autoimmune disease who received combination ipilimumab and anti-PD1 at 10 international centers from March 2015 to February 2020. Data regarding the autoimmune disease, treatment, toxicity and outcomes were examined in patients. Results: Of the 55 patients who received ipilimumab and anti-PD1, the median age was 63 years (range 23-83). Forty-six were treated with ipilimumab and nivolumab and nine with ipilimumab and pembrolizumab.Eighteen patients (33%) had a flare of their autoimmune disease including 4 of 7 with rheumatoid arthritis, 3 of 6 with psoriasis, 5 of 10 with inflammatory bowel disease, 3 of 19 with thyroiditis, 1 of 1 with Sjogren's syndrome, 1 of 1 with polymyalgia and 1 of 1 with Behcet's syndrome and psoriasis. Eight (44%) patients ceased combination therapy due to flare. Thirty-seven patients (67%) had an unrelated immune-related adverse event (irAE), and 20 (36%) ceased combination immunotherapy due to irAEs. There were no treatment-related deaths. Patients on immunosuppression (OR 4.59; p=0.03) had a higher risk of flare.The overall response rate was 55%, with 77% of responses ongoing. Median progression free survival and overall survival were 10 and 24 months, respectively. Patients on baseline immunosuppression had an overall survival of 11 months (95% CI 3.42 to 18.58) compared with 31 months without (95% CI 20.89 to 41.11, p=0.005). Conclusions: In patients with pre-existing autoimmune disease, not on immunosuppression and advanced melanoma, combination ipilimumab and anti-PD1 has similar efficacy compared with previously reported trials. There is a risk of flare of pre-existing autoimmune disorders, particularly in patients with inflammatory bowel disease and rheumatologic conditions, and patients on baseline immunosuppression.
[Stent rupture with subsequent balloon catheter failure and entrapment under stent during elective angioplasty at the right coronary artery].

A. Gziut,A. Słysz,P. Seweryniak,Rafał Krzyżewski,M. Furmanek

Kardiologia Polska

Abstract:Adres do korespondencji: dr n. med. Aneta I. Gziut, Klinika Kardiologii Inwazyjnej, Centralny Szpital Kliniczny MSWiA, ul. Wołoska 137, 02-507 Warszawa, tel.: +48 22 508 11 00, faks: +48 22 845 41 30, e-mail: kardiologia.inwazyjna@cskmswia.pl Przedstawiamy przypadek 54-letniego chorego hospitalizowanego 3-krotnie w Klinice Kardiologii Inwazyjnej w związku z powikłaniem zabiegu angioplastyki wieńcowej.
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure

Gina Klee,Jonas Kurzhals,Victoria Hagelstein,Detlef Zillikens,Andreas Recke,Ewan A Langan,Patrick Terheyden,Ewan A. Langan

DOI: https://doi.org/10.1097/cmr.0000000000000760

2021-07-19

Melanoma Research

Abstract:Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined with anti-PD-1 immunotherapy in patients who progressed after anti-PD-1 monotherapy. Nine patients with unresectable stage III or IV melanoma treated with combined low-dose ipilimumab (1 mg/kg, IPI1) and anti-PD-1 immunotherapy, following progression after anti-PD-1 treatment, were identified. Treatment response and irAEs were recorded. Grade 3 irAEs occurred in one-third of patients. Interestingly, there were no grade 4 or 5 irAEs. In fact, four out of the nine patients experienced no irAEs at all. One patient discontinued combined immunotherapy due to immune-related colitis. The mean time to the onset of grade 3 irAEs was 14.3 weeks. The objective response rate was 33.3% and a disease control rate of 66.7% was achieved. Median progression-free survival (PFS) was 5.7 months and median overall survival (OS) was 21.6 months. The median PFS when IPI1 and anti-PD-1 treatment was administered in the second-line setting was not reached, but only 2.8 months when used in subsequent treatment settings. Combined IPI1 and anti-PD-1 immunotherapy was well tolerated. Its use in the third-line or above setting was associated with a significantly poorer prognosis than in the second-line setting. Larger, prospective studies are required to evaluate the safety and efficacy of this dosing regimen following anti-PD-1 treatment failure.

dermatology,oncology,medicine, research & experimental
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Troy Z Horvat,Nelly G Adel,Thu-Oanh Dang,Parisa Momtaz,Michael A Postow,Margaret K Callahan,Richard D Carvajal,Mark A Dickson,Sandra P D'Angelo,Kaitlin M Woo,Katherine S Panageas,Jedd D Wolchok,Paul B Chapman

DOI: https://doi.org/10.1200/JCO.2015.60.8448

2015-10-01

Abstract:Purpose: Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy and the effect of these therapies on overall survival (OS) and time to treatment failure (TTF). Patients and methods: We reviewed retrospectively the medical records of patients with melanoma who had received treatment between April 2011 and July 2013 with ipilimumab at the standard dose of 3 mg/kg. We collected data on patient demographics, previous and subsequent treatments, number of ipilimumab doses, irAEs and how they were treated, and overall survival. Results: Of the 298 patients, 254 (85%) experienced an irAE of any grade. Fifty-six patients (19%) discontinued therapy because of an irAE, most commonly diarrhea. Overall, 103 patients (35%) required systemic corticosteroid treatment for an irAE; 29 (10%) also required anti-TNFα therapy. Defining TTF as either starting a new treatment or death, estimated median TTF was 5.7 months. Twelve percent of patients experienced long-term disease control without receiving additional antimelanoma therapy. OS and TTF were not affected by the occurrence of irAEs or the need for systemic corticosteroids. Conclusion: IrAEs are common in patients treated with ipilimumab. In our experience, approximately one-third of ipilimumab-treated patients required systemic corticosteroids, and almost one-third of those required further immune suppression with anti-TNFα therapy. Practitioners and patients should be prepared to treat irAEs and should understand that such treatment does not affect OS or TTF.
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Jens Tijtgat,Xenia Geeraerts,Anais Boisson,Latoya Stevens,Manon Vounckx,Iris Dirven,Julia Katharina Schwarze,Steven Raeymaeckers,Ramses Forsyth,Ivan Van Riet,Sandra Tuyaerts,Karen Willard-Gallo,Bart Neyns

DOI: https://doi.org/10.1136/jitc-2023-008148

IF: 12.469

2024-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Patients with advanced melanoma who progress after treatment with immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective treatment options. The presence of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells (myDC) in the tumor microenvironment correlates with pre-existing immune recognition and responsiveness to immune checkpoint blockade. The synthetic saponin-based immune adjuvant AS01 B enhances adaptive immunity through the involvement of myDC. Methods In this first-in-human phase I clinical trial, patients with metastatic melanoma refractory to ICI and BRAF-/MEK inhibitors (when indicated) were recruited. Patients received an intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus an intratumoral (IT) administration of 10 mg ipilimumab and 50 μg (0.5 mL) AS01 B (every 2 weeks). All myDC, isolated from blood, were injected on day 2 into the same metastatic lesion. Tumor biopsies and blood samples were collected at baseline and repeatedly on treatment. Multiplex immunohistochemistry (mIHC) was performed on biopsy sections to characterize and quantify the IT and peritumoral immune cell composition. Results Study treatment was feasible and well tolerated without the occurrence of unexpected adverse events in all eight patients. Four patients (50%) obtained a complete response (CR) in the injected lesions. Of these, two patients obtained an overall CR, and one patient a partial response. All responses are ongoing after more than 1 year of follow-up. One additional patient had a stable disease as best response. The disease control rate was 50%. Median progression-free survival and overall survival were 24.1 and 41.9 weeks, respectively. Baseline tumor biopsies from patients who responded to treatment had features of T-cell exclusion. During treatment, there was an increased T-cell infiltration, with a reduced mean distance between T cells and tumor cells. Peripheral blood immune cell composition did not significantly change during study treatment. Conclusions Combining an intratumoral injection of CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC with repeated IT administration of ipilimumab and AS01 B and systemic low-dose nivolumab is safe, feasible with promising early results, worthy of further clinical investigation. Trial registration number ClinicalTrials.gov identifier NCT03707808 .

oncology,immunology
A Phase I Trial of Ipilimumab Plus Bevacizumab in Patients with Unresectable Stage Iii or Stage Iv Melanoma

F. S. Hodi,P. A. Friedlander,M. B. Atkins,D. F. McDermott,D. P. Lawrence,N. Ibrahim,X. Wu,J. Zhou,A. Giobbie-Hurder,G. Murphy,T. Hollman,E. Velazquez,S. Russell,P. Dipiro,J. T. Yap,A. D. Van den Abbeele

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8511

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:8511 Background: CTLA-4 blockade with ipilimumab demonstrated a survival advantage in advanced melanoma. Ipilimumab induces an immune mediated tumor vasculopathy. In addition to angiogenic effects, VEGF is a potent immune suppressor of antigen presenting cells. Therefore, we performed the first combination study to investigate potential synergies of ipilimumab and bevacizumab. Methods: Patients (pts) were eligible with stage III unresectable or stage IV disease, no bowel or CNS metastases, ECOG PS 0 or 1, > 4 wks from prior therapy, adequate end organ function, no autoimmune or bleeding problems. Pts received ipilimumab every 3 weeks IV x 4 then q12 weeks, and bevacizumab q 3 weeks. Pts could continue if good PS with up to 40% increase in the sum of the longest diameter and no more than 2 new target lesions. Cohort 1 comprised 10 mg/kg ipilimumab plus 7.5 mg/kg bevacizumab. If ≥3/5 pts did not experience DLT then cohort 2 could be enrolled at 10 mg/kg ipilimumab plus 15 mg/kg bevacizumab. An additional 12 patients could be treated at MTD. Results: 22 pts treated with 21 pts currently evaluable. Side effects included giant cell arteritis(1), hypophysitis(3), thyroiditis(4), grade 3-4 hepatitis(2), bilateral uveitis(2), and grade 2 colitis(2); 5 pts required systemic steroids and stopping treatment. All toxicities resolved. PET revealed early response activity and perfusion CT demonstrated persistent decreased tumor blood flow. Best overall response to date includes 8 partial responses and 6 stable disease. All responses are durable (>6mos). Median TTP has not yet been achieved. Post-treatment biopsies in 12 pts revealed activated vessel endothelium with extensive T cell trafficking not seen with ipilimumab alone, as well as non-productive central angiogenesis. Peripheral blood monitoring revealed marked increase in CD4/CCR7/CD45RO central memory cells in majority of patients, not seen with ipilimumab alone. Conclusions: Ipilimumab plus bevacizumab can be safely administered, with management of noted toxicities. Clinical activity and correlatives suggest synergistic effects, with 14/21 pts experiencing clinical benefit. This combination merits further exploration, with additional efforts underway.
Direct effects of estradiol benzoate and testosterone on the response of the male rat pituitary to luteinizing hormone releasing hormone (LHRH).

G. Greeley,I. Volcan,V. B. Mahesh

DOI: https://doi.org/10.1095/BIOLREPROD18.2.256

1978-03-01

Biology of Reproduction

Abstract:Castrated male rats with pituitary stalk sections (CSS rats) were used to examine the direct actions of estradiol benzoate (EB) or testosterone (T) upon LHRH induced gonadotrophin release. Using a ventral approach, the pituitary stalk was severed and a barrier placed between the divided ends to prevent vascular regeneration. Data indicative of a separation of the pituitary from direct hypothalamic control were the significant diminitions of LH and FSH in sera of castrated rats. In both unprimed and LHRH-primed CSS rats, gonadotrophmn secreting cells remain responsive to exogenous LHRH. After a 14-day recovery period, CSS rats were pretreated with LFIRH only or LI-IRH plus EB or T for 6 days. Sixteen to 18 h after their last pretreatment injections, CSS rats were challenged with 5 or 20 ng LHRH. The resting levels of LH and FSH values in the sera of CSS rats treated with LHRH only or with LHRU plus EB or T were similar to those of untreated CSS rats. The sera LH responses to the 5 ng dose of LHRH in the EB-treated CSS rats (1 Mg/kgBW 18 h before, or 800 ,ig/kgBW 3 h before LHRH challenge) were similar to those of CSS rats pretreated with LHRH only. In contrast, ER-priming (1 or 10 12g/kgBW) significantly enhanced (P<0.05) the sera LH response to 20 ng LHRH. Pretreatment with T (250 �g or 2.5 mg/kgBW) led to a decrease of the sera LH response to 5ng LHRH. Using 20 ng LHRH, both T (2.5 mg/kgBW) and EB (1 or 10 Mg/kgBW) augmented the magnitudes of the sera LU responses. Compared to the 1 Mg/kgBW EB-treated group, the LU releasing action of LHRH is prolonged in the 10 Mg/kgBW EB-pretreated group. No consistent effect of LHRH upon FSH release alone or in combination with EB or T priming was observed. While intraarterial administration of LHRH did not show any change in FSH release, i.v. administration appeared to stimulate it. Our results indicated that the modifying action of EB or T at the pituitary seemed to be related to the quantity of both the steroid used for priming and the challenging dose of LHRH, since both affected LU release.
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease

Huaqi Li,Scott Huntington,Cary Gross,Shi-Yi Wang

DOI: https://doi.org/10.1371/journal.pone.0300789

IF: 3.7

2024-04-16

PLoS ONE

Abstract:Purpose Immunotherapy has been shown to improve cancer survival, but there are no consensus guidelines to inform use in patients with both cancer and autoimmune disease (AD). We sought to examine immunotherapy utilization patterns between cancer patients with and without AD. Patients and methods This retrospective cohort study utilized data from a de-identified nationwide oncology database. Patients diagnosed with advanced melanoma, non-small cell lung cancer, and renal cell carcinoma were included. Outcomes of interest included first-line immunotherapy, overall immunotherapy, and number of immunotherapy cycles. We used logistic and Poisson regression models to examine associations between AD and immunotherapy utilization patterns. Results A total of 25,076 patients were included (796 with AD). Patients with AD were more likely to be female, White, receive care at academic centers, and have ECOG ≥ 3. Controlling for demographic and clinical variables, AD was associated with lower odds of receiving first-line (odds ratio [OR] = 0.68, 95% confidence interval [CI] 0.56–0.82) and overall (OR = 0.80, 95% CI 0.67–0.94) immunotherapy. Among patients who received at least one cycle of immunotherapy, there was no difference in mean number of cycles received between patients with and without AD (11.3 and 10.5 cycles respectively). The incident rate of immunotherapy cycles received for patients with AD was 1.03 times that of patients without AD (95% CI 1.01–1.06). Discussion Patients with AD were less likely to receive immunotherapy as first-line and overall therapy for treatment of their advanced cancer. However, among those who did receive at least one cycle of immunotherapy, patients with AD received a similar number of cycles compared to patients without AD. This not only indicates that AD is not an absolute contraindication for immunotherapy in clinical practice but may also demonstrate overall treatment tolerability and net benefit in patients with AD.

multidisciplinary sciences
Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Katharina C. Kähler,Jessica C. Hassel,Lucie Heinzerling,Carmen Loquai,Kai‐Martin Thoms,Selma Ugurel,Lisa Zimmer,Ralf Gutzmer,ADO) for the committee on “Cutaneous Adverse Events“ of the German Working Group for Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie,

DOI: https://doi.org/10.1111/ddg.14128

2020-06-01

Abstract:<p>CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti‐CTLA‐4 and anti‐PD‐1 antibodies affect the interaction between tumor, antigen‐presenting cells and T lymphocytes. Clinical studies of the anti‐CTLA‐4 antibody ipilimumab and the anti‐PD‐1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five‐year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with adverse events. Knowledge of the spectrum of side effects is essential, both in terms of prevention and management. Adverse events include colitis, dermatitis, hypophysitis, thyroiditis, hepatitis and other, less common autoimmune phenomena. In recent years, considerable progress has been made in the detection and treatment of the aforementioned immune‐related adverse events. However, early diagnosis of rare neurological or cardiac side effects, which may be associated with increased mortality, frequently pose a challenge. The present update highlights our current understanding as well as new insights into the spectrum of side effects associated with checkpoint inhibitors and their management.</p>
Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution

Federico Venturi,Giulia Veronesi,Biagio Scotti,Emi Dika

DOI: https://doi.org/10.3390/cancers16213679

2024-10-31

Cancers

Abstract:Background/Objectives: The landscape of advanced melanoma treatments has shifted dramatically in recent years. Target therapy and immunotherapy have changed the management of patients with both metastatic (stage IV according to AJCC 8th ed.) and nodal (stage IIB/C and III) disease. As the use of novel agents has increased, so have the cutaneous toxicities associated with these medications. While most skin reactions are low-grade and can be managed conservatively with topical therapies, high-grade or life-threatening drug reactions can arise during therapy, requiring prompt dermatologic recognition and treatment. Given the survival benefit attributed to these new agents, treating skin toxicity and maintaining a patient's quality of life is of paramount importance. Methods: We undertook a prospective, monocentric, and descriptive study in Bologna, Italy, including patients referred to the Oncologic Dermatology Unit of IRCCS AOU of Bologna who developed biopsy-proven cutaneous adverse events (AE) under treatment with immunotherapy for cutaneous melanoma with nodal (stage IIB/C, III) and metastatic (stage IV) disease from January 2016 to April 2024. Results: In 202 identified patients, 75 (37.5%) developed skin AEs. Ipilimumab was causal for 48.1% of skin AEs, followed by nivolumab (37%) and pembrolizumab (31.4%). Recorded types of skin AEs included erythematous rash, vitiligo, alopecia, lichenoid, maculopapular, acneiform, urticarial, psoriasiform, granulomatous, eczematous, and severe cutaneous AEs, such as Erythema multiforme/Stevens-Johnson syndrome and bullous autoimmune dermatoses. Most AEs were low-grade [CTCAE 1–2] (97%) and typically occurred after 10 weeks of treatment. Conclusions: This study comprehensively describes skin AEs occurring during systemic treatment with ICIs for cutaneous melanoma at a single center.

oncology
The site of action of 2,4-dinitrophenol and salicylic acid upon the uncoupler-induced K+ efflux from non-metabolizing yeast.

J. Hoeberichts,Th.J.M. Hulsebos,P.M.G.F. Van Wezenbeek,G. Borst-Pauwels

DOI: https://doi.org/10.1016/0005-2736(80)90254-0

1980-01-12

Biochimica et Biophysica Acta

Abstract:
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Ari VanderWalde,Shay L. Bellasea,Kari L. Kendra,Nikhil I. Khushalani,Katie M. Campbell,Philip O. Scumpia,Lawrence F. Kuklinski,Frances Collichio,Jeffrey A. Sosman,Alexandra Ikeguchi,Adrienne I. Victor,Thach-Giao Truong,Bartosz Chmielowski,David C. Portnoy,Yuanbin Chen,Kim Margolin,Charles Bane,Constantin A. Dasanu,Douglas B. Johnson,Zeynep Eroglu,Sunandana Chandra,Egmidio Medina,Cynthia R. Gonzalez,Ignacio Baselga-Carretero,Agustin Vega-Crespo,Ivan Perez Garcilazo,Elad Sharon,Siwen Hu-Lieskovan,Sapna P. Patel,Kenneth F. Grossmann,James Moon,Michael C. Wu,Antoni Ribas

DOI: https://doi.org/10.1038/s41591-023-02498-y

IF: 82.9

2023-08-18

Nature Medicine

Abstract:In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free survival. Secondary endpoints included the difference in CD8 T cell infiltrate among responding and nonresponding tumors, objective response rate, overall survival and toxicity. The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio = 0.63, 90% confidence interval (CI) = 0.41–0.97, one-sided P = 0.04). Objective response rates were 28% (90% CI = 19–38%) and 9% (90% CI = 2–25%), respectively (one-sided P = 0.05). Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens. The change in intratumoral CD8 T cell density observed in the present analysis did not reach statistical significance to support the formal hypothesis tested as a secondary endpoint. In conclusion, primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade. Clinicaltrials.gov identifier: NCT03033576.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Ahmad A Tarhini,Ni Kang,Sandra J Lee,F Stephen Hodi,Gary I Cohen,Omid Hamid,Laura F Hutchins,Jeffrey A Sosman,Harriet M Kluger,Zeynep Eroglu,Henry B Koon,Donald P Lawrence,Kari L Kendra,David R Minor,Carrie B Lee,Mark R Albertini,Lawrence E Flaherty,Teresa M Petrella,Howard Streicher,Vernon K Sondak,John M Kirkwood

DOI: https://doi.org/10.1136/jitc-2021-002535

Abstract:Background: The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood. Patients and methods: E1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus interferon-α. We investigated the association of irAEs and of use of immunosuppressants with RFS and OS for patients treated with ipilimumab (n=1034). Results: Occurrence of grades 1-2 irAEs was associated with RFS (5 years: 52% (95% CI 47% to 56%) vs 41% (95% CI 31% to 50%) with no AE; p=0.006) and a trend toward improved OS (5 years: 75% (95% CI 71% to 79%) compared with 67% (95% CI 56% to 75%) with no AE; p=0.064). Among specific irAEs, grades 1-2 rash was most significantly associated with RFS (p=0.002) and OS (p=0.003). In multivariate models adjusting for prognostic factors, the most significant associations were seen for grades 1-2 rash with RFS (p<0.001, HR=0.70) and OS (p=0.01, HR=0.71) and for grades 1-2 endocrine+rash with RFS (p<0.001, HR=0.66) and OS (p=0.008, HR=0.7). Overall, grades 1-2 irAEs had the best prognosis in terms of RFS and OS and those with grades 3-4 had less RFS benefits and no OS advantage over no irAE. Patients experiencing grades 3-4 irAE had significantly higher exposure to corticosteroids and immunosuppressants than those with grades 1-2 (92% vs 60%; p<0.001), but no significant associations were found between corticosteroid and immunosuppressant use and RFS or OS. In investigating the impact of non-corticosteroid immunosuppressants, although there were trends toward better RFS and OS favoring cases who were not exposed, no significant associations were found. Conclusions: Rash and endocrine irAEs were independent prognostic factors of RFS and OS in patients treated with adjuvant ipilimumab. Patients experiencing lower grade irAEs derived the most benefit, but we found no significant evidence supporting a negative impact of high dose corticosteroids and immunosuppressants more commonly used to manage grades 3-4 irAEs.
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis

N N Alrabadi,H M Abushukair,O E Ababneh,S S Syaj,S S Al-Horani,A A Qarqash,O A Darabseh,M M Al-Sous,S R Al-Aomar,Y B Ahmed,R Haddad,F A Al Qarqaz

DOI: https://doi.org/10.1007/s12094-021-02598-6

Abstract:Background: More than half of melanoma patients taking first-line anti-PD-1 therapy either express transient or no response at all. The efficacy and safety of secondary treatments for these patients are still not well established. Here, we evaluate the efficacy and safety of different melanoma FDA-approved ICI modalities used in post-anti-PD-1 refractory settings. Materials and methods: We searched the PubMed database and the ASCO meetings library for studies on advanced melanoma patients with cancer progression on anti-PD-1 therapy and were then treated with ipilimumab, nivolumab/ipilimumab combination, or retreated with anti-PD-1. Primary and secondary endpoints were efficacy and toxicity, respectively. Pooled estimates for each treatment group were obtained using a random or fixed effects model according to detected heterogeneity. Results: Fourteen studies, of which 10 on ipilimumab, 2 on anti-PD-1 treatment, and 6 on combination therapies, were included, involving a total of 1460 patients. Twelve studies reported objective response rates (ORRs) and nine of them reported immune-related adverse events (irAEs). As for ORR, patients experienced a response that was inferior compared to the same therapy in treatment -naïve patients, with combination therapy having the best ORR of a pooled 23.08% (95% CI: 16.75% to 30.03%), followed by ipilimumab with a pooled ORR of 8.19% (95% CI: 5.78% to 10.92%). Survival data were also inferior in the ipilimumab cohort (mOS: 5.1 to 7.4 months) compared to ipilimumab in anti-PD-1 naive patients. As for grade 3/4 irAE occurrence, the ipilimumab cohort showed an estimate of 43.77% (95% CI 22.55% to 66.19%). Conclusion: Our findings provide the best current evidence that patients who progress on anti-PD-1 can still respond to different ICI modalities (ipilimumab with or without nivolumab, and retreatment or continuation beyond progression with anti-PD-1) with tolerable grade 3/4 irAEs. However, more prospective clinical trials are needed to confirm these results.
Treatment of Peroneal Nerve Injuries in the Multiligament Injured/Dislocated Knee

Michael P. O’Malley,Ayoosh Pareek,Patrick J. Reardon,A. Krych,M. Stuart,B. Levy

DOI: https://doi.org/10.1055/s-0035-1570019

2015-12-18

The Journal of Knee Surgery

Abstract:Abstract Tibiofemoral knee dislocations are typically a consequence of high-energy mechanisms, causing significant damage to the soft tissue and osseous structures of the knee. Concomitant neurovascular injuries such as popliteal artery and peroneal nerve injuries are also common and can have significant long-term consequences. The mechanism typically involves a traction injury to the peroneal nerve subsequent to an extreme varus moment applied to the knee. Complete nerve injuries typically hold a worse prognosis than incomplete palsies. Rates of functional recovery in the setting of a complete palsy following a knee dislocation event have been dismal. A period of observation and nonoperative treatment is initially performed, utilizing orthotic devices to assist with lower extremity deficits. Surgical treatment options include neurolysis, nerve grafting, tendon transfer, arthrodesis, and direct motor nerve transfers. Motor nerve transfers continue to be explored with initial reports showing promising results.
Life-history responses of Daphnia magna Straus to binary mixtures of toxic substances: pharmacological versus ecotoxicological modes of action.

C. Barata,D. Baird,A. Nogueira,A. R. Agra,A. Soares

DOI: https://doi.org/10.1016/J.AQUATOX.2007.07.004

IF: 5.202

2007-10-30

Aquatic Toxicology

Abstract:
Cardiovascular Health Issues in Inner City Populations.

Dhruv Nayyar,Stephen W. Hwang

DOI: https://doi.org/10.1016/j.cjca.2015.04.011

IF: 6.614

2015-09-01

Canadian Journal of Cardiology

Abstract:
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Theodoros G. Soldatos,Antonia Dimitrakopoulou-Strauss,Lionel Larribere,Jessica C. Hassel,Christos Sachpekidis

DOI: https://doi.org/10.3390/diagnostics8040076

IF: 3.6

2018-10-31

Diagnostics

Abstract:Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their safety profile combines reactions from each drug alone. While more prospective studies are needed to characterize the safety of ipilimumab and nivolumab, the present work constitutes perhaps the first effort to examine the safety of these drugs and their combination based on computational evidence from real world post marketing data.

medicine, general & internal

High plasma calcium and influencing factors in interstitial plasma cell pneumonia in infants.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

[Stent rupture with subsequent balloon catheter failure and entrapment under stent during elective angioplasty at the right coronary artery].

Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

A Phase I Trial of Ipilimumab Plus Bevacizumab in Patients with Unresectable Stage Iii or Stage Iv Melanoma

Direct effects of estradiol benzoate and testosterone on the response of the male rat pituitary to luteinizing hormone releasing hormone (LHRH).

Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution

The site of action of 2,4-dinitrophenol and salicylic acid upon the uncoupler-induced K+ efflux from non-metabolizing yeast.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis

Treatment of Peroneal Nerve Injuries in the Multiligament Injured/Dislocated Knee

Life-history responses of Daphnia magna Straus to binary mixtures of toxic substances: pharmacological versus ecotoxicological modes of action.

Cardiovascular Health Issues in Inner City Populations.

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data